The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
Open accessAbstract
BACKGROUND: In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality from coronary heart disease and overall mortality have remained uncertain. METHODS: In a double-blind, randomized trial, we compared the effects of pravastatin (40 mg daily) with those of a placebo over a mean follow-up period of 6.1 years in 9014 patients who were 31 to 75 years of age. The patients had a history of myocardial infarction or hospitalization for unstable angina and initial plasma total cholesterol levels of 155 to 271 mg per deciliter. Both groups received advice on following a cholesterol-lowering diet. The primary study outcome was mortality from coronary heart disease. RESULTS: Death from coronary heart disease occurred in 8.3 percent of the patients in the placebo group and 6.4 percent of those in the pravastatin group, a relative reduction in risk of 24 percent (95 percent confidence interval, 12 to 35 percent; P<0.001). Overall mortality was 14.1 percent in the placebo group and 11.0 percent in the pravastatin group (relative reduction in risk, 22 percent; 95 percent confidence interval, 13 to 31 percent; P<0.001). The incidence of all cardiovascular outcomes was consistently lower among patients assigned to receive pravastatin; these outcomes included myocardial infarction (reduction in risk, 29 percent; P<0.001), death from coronary heart disease or nonfatal myocardial infarction (a 24 percent reduction in risk, P<0.001), stroke (a 19 percent reduction in risk, P=0.048), and coronary revascularization (a 20 percent reduction in risk, P<0.001). The effects of treatment were similar for all predefined subgroups. There were no clinically significant adverse effects of treatment with pravastatin. CONCLUSIONS: Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A large body of evidence indicates that statin-based strategies convey similar LDL-C lowering and relative cardiovascular risk reduction in patients with and those without T2DM.102–112”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [103]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data from RCTs and meta-analyses indicate that routine early use of high-intensity statin therapy is associated with rapid and sustained clinical benefits [438-442].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [442]
Experimental — accuracy not yet measuredIn the citing paper
“Although healthy lifestyle habits remain a cornerstone of T2DM management, trial data have confirmed the additional benefits of statin therapy in the primary and secondary prevention of CAD.13,102–112”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [103]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9-45% in patients with CAD.22,180”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [22]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9-45% in patients with CAD. 368,369”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [369]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9e45% in patients with CAD.368,369”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [369]
In the citing paper
“It was demonstrated in the REACH registry, a registry study on patients with ASCVD or overlapping risks factors for ASCVD, that approximately 16% registered cases are complicated with two or more ASCVD757).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [757]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,851
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960
EUROASPIRE Study Group (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015136 · Cited by 665
Chen, Z., Peto, R., Collins, R., MacMahon, S. W., Lu, J., & Li, W. (1991) · BMJ · doi:10.1136/bmj.303.6797.276 · Cited by 537
Research works printed but not linked: 4
- Peto R, 1985, Circulation, 72, 451
- Keech A, 1992, Postgrad Med J, 68, 870
- 1994, Lancet, 344, 1383
- Keech A, 1998, Atherosclerosis, 136, S31
Cited by
Sorted by citations
Items 701–800 of 1,037
SUTTER, J. D., Tavernier, R., Buyzere, M. D., Jordaens, L. J. L. M., & Backer, G. D. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00787-7 · Cited by 121
Lipoprotein (a) and stroke: Table 1
Milionis, H. J., WINDER, A. F., & Mikhailidis, D. P. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.7.487 · Cited by 121
Cholesterol Lowering in the Elderly Population
Grundy, S. M. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.15.1670 · Cited by 121
Effect of statin therapy on restenosis after coronary stent implantation
Malik, I. S., Khan, M., & Beatt, K. J. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01156-5 · Cited by 121
Sarkar, U., Lyles, C. R., Parker, M. M., Allen, J. Y., Nguyen, R., Moffet, H. H., Schillinger, D., & Karter, A. J. (2013) · Medical Care · doi:10.1097/mlr.0000000000000069 · Cited by 120
Montagnani, A., Gonnelli, S., Cepollaro, C., Pacini, S., Campagna, M. S., Franci, M. B., Lucani, B., & Gennari, C. (2003) · Bone · doi:10.1016/s8756-3282(03)00034-6 · Cited by 120
2023 China Guidelines for Lipid Management
Li, J., Zhao, S., Zhao, D., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2023.09.008 · Cited by 120
Volpe, R. J., Niittynen, L., Korpela, R., Sirtori, C. R., Bucci, A., Fraone, N., & Pazzucconi, F. (2001) · British Journal Of Nutrition · doi:10.1079/bjn2001395 · Cited by 120
Delbosc, S., Morena-Carrere, M., Djouad, F., Ledoucen, C., Descomps, B., & Cristol, J. (2002) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200210000-00015 · Cited by 120
Effect of statin therapy on restenosis after coronary stent implantation
Walter, D. H., Schächinger, V., Elsner, M., Mach, S., Auch–Schwelk, W., & Zeiher, A. M. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00910-8 · Cited by 120
Vita, J. A., Yeung, A. C., Winniford, M. D., Hodgson, J. M., Treasure, C. B., Klein, J. L., Werns, S. W., Kern, M. J., Plotkin, D. J., Shih, W., et al. (2000) · Circulation · doi:10.1161/01.cir.102.8.846 · Cited by 120
Lytras, T. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1858 · Cited by 119
Review of Trials in Chronic Heart Failure Showing Broad-Spectrum Anti-Inflammatory Approaches
Gullestad, L. L., & Aukrust, P. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.03.008 · Cited by 119
Nissen, S. E. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.013 · Cited by 119
Li, D. X. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00371-6 · Cited by 119
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
Patel, T. N., Shishehbor, M. H., & Bhatt, D. L. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl445 · Cited by 119
Moyle, G. J., Lloyd, M., Reynolds, B., Baldwin, C., Mandalia, S., & Gazzard, B. (2001) · AIDS · doi:10.1097/00002030-200108170-00007 · Cited by 119
The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
Fazio, S., & Linton, M. F. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0104-8 · Cited by 118
Walter, D. H., Fichtlscherer, S., Britten, M. B., Rosin, P., Auch–Schwelk, W., Schächinger, V., & Zeiher, A. M. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01662-x · Cited by 118
Terblanche, M., Almog, Y., Rosenson, R. S., Smith, T. S., & Hackam, D. G. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70439-x · Cited by 118
Kosoglou, T., Meyer, I., Veltri, E. P., Statkevich, P., Yang, B., Zhu, Y., Mellars, L., Maxwell, S. E., Patrick, J. E., Cutler, D. L., et al. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01633.x · Cited by 117
Ramos, R., García-Gil, M., Comas‐Cufí, M., Quesada, M., Marrugat, J., Elosúa, R., Sala, J., Grau, M., Martí‐Lluch, R., Ponjoan, A., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.052 · Cited by 117
Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?
Reid, F., Cook, D. G., & Whincup, P. H. (2002) · Heart · doi:10.1136/heart.88.1.15 · Cited by 117
A Comprehensive Description of Muscle Symptoms Associated with Lipid-Lowering Drugs
Franc, S., Dejager, S., Bruckert, É., Chauvenet, M., Giral, P., & Turpin, G. (2003) · Cardiovascular Drugs and Therapy · doi:10.1023/b:card.0000015861.26111.ab · Cited by 117
Yokoyama, M., & Origasa, H. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00367-3 · Cited by 117
Seljeflot, I., Tonstad, S., Hjermann, I., & Arnesen, H. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00696-7 · Cited by 117
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Navaneethan, S. D., Pansini, F., Perkovic, V., Manno, C., Pellegrini, F., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784 · Cited by 117
Simvastatin induces impairment in skeletal muscle while heart is protected
Sirvent, P., Bordenave, S., Vermaelen, M., Roels, B., Vassort, G., Mercier, J., Raynaud, E., & Lacampagne, A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.108 · Cited by 116
Statins and the Brain: More than Lipid Lowering Agents?
Fracassi, A., Marangoni, M., Rosso, P., Pallottini, V., Fioramonti, M., Siteni, S., & Segatto, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170703101816 · Cited by 116
Myopathy in older people receiving statin therapy: a systematic review and meta‐analysis
Iwere, R. B., & Hewitt, J. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12687 · Cited by 116
Boudreau, D. M., Gardner, J. S., Malone, K. E., Heckbert, S. R., Blough, D. K., & Daling, J. R. (2004) · Cancer · doi:10.1002/cncr.20271 · Cited by 116
Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy
Benner, J. S., Tierce, J. C., Ballantyne, C. M., Prasad, C., Bullano, M. F., Willey, V. J., Erbey, J., & Sugano, D. S. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422003-00003 · Cited by 115
Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue
Parisi, V., Petraglia, L., D'Esposito, V., Cabaro, S., Rengo, G., Caruso, A., Grimaldi, M. G., Baldascino, F., De Bellis, A., Vitale, D., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.06.106 · Cited by 114
Sarkisian, C. A., Brown, A. F., Norris, K. C., Wintz, R. L., & Managione, C. M. (2003) · The Diabetes Educator · doi:10.1177/014572170302900311 · Cited by 114
Statin‐Associated Muscle‐Related Adverse Effects: A Case Series of 354 Patients
Cham, S., Evans, M. A., Denenberg, J. O., & Golomb, B. A. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.6.541 · Cited by 114
Predictive value of LDL/HDL ratio in coronary atherosclerotic heart disease
Sun, T., Chen, M., Shen, H., PingYin, Li, F., Chen, X., Wu, J., Xu, Z., & Zhang, J. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02706-6 · Cited by 114
Saitō, Y., Yamada, N., Teramoto, T., Itakura, H., Yoshiya, H. A. T. A., Nakaya, N., Mabuchi, H., Tushima, M., Sasaki, J., & Ogawa, N. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00712-2 · Cited by 114
Keating, G. M., & Ormrod, D. J. (2002) · Drugs · doi:10.2165/00003495-200262130-00013 · Cited by 114
Use and Monitoring of "Statin" Lipid-Lowering Drugs Compared With Guidelines
Abookire, S. A., Karson, A. S., Fiskio, J. M., & Bates, D. W. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.1.53 · Cited by 114
Duncan, R. E., El-Sohemy, A., & Archer, M. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400732200 · Cited by 113
Review article: drug-induced liver injury - its pathophysiology and evolving diagnostic tools
Au, J. S., Navarro, V. J., & Rossi, S. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04674.x · Cited by 113
Statins Reduce the Risk of Pancreatic Cancer in Humans
Khurana, V., Sheth, A. R., Caldito, G. C., & Barkin, J. S. (2007) · Pancreas · doi:10.1097/mpa.0b013e318030e963 · Cited by 113
Statins, Low-Density Lipoprotein Cholesterol, and Risk of Cancer
Alsheikh-Ali, A. A. A., Trikalinos, T. A., Kent, D. M., & Karas, R. H. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.06.037 · Cited by 113
Emerging views of statin pleiotropy and cholesterol lowering
Yu, D., & Liao, J. K. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab032 · Cited by 113
Caterina, R. D., Cipollone, F., Filardo, F. P., Zimarino, M., Bernini, W., Lazzerini, G., Bucciarelli, T., Falco, A., Marchesani, P., Muraro, R., et al. (2002) · Circulation · doi:10.1161/01.cir.0000038500.43292.d7 · Cited by 113
Frolkis, J. P., Pearce, G. L., Nambi, V., Minor, S., & Sprecher, D. L. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01303-7 · Cited by 113
Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm
Ferraro, R., Latina, J. M., Alfaddagh, A., Michos, E. D., Blaha, M. J., Jones, S. R., Sharma, G. V., Trost, J. C., Boden, W. E., Weintraub, W. S., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.078 · Cited by 114
Cardiovascular Morbidity Associated with Nonadherence to Statin Therapy
Blackburn, D. F., Dobson, R. T., Blackburn, J. L., & Wilson, T. W. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.8.1035 · Cited by 112
Kruithof, E. K. O. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-04-0269 · Cited by 112
HMG-CoA reductase inhibitors (statins)
Hess, D. C., Demchuk, A. M., Brass, L. M., & Yatsu, F. M. (2000) · Neurology · doi:10.1212/wnl.54.4.790 · Cited by 112
Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required
Superko, H. R., & King, S. B. (2008) · Circulation · doi:10.1161/circulationaha.106.667428 · Cited by 112
Discontinuation of statin therapy due to muscular side effects: A survey in real life
Rosenbaum, D., Dallongeville, J., Sabouret, P., & Bruckert, E. (2013) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.04.012 · Cited by 111
Red Yeast Rice for Hypercholesterolemia
Cicero, A. F. G., Fogacci, F., & Zambon, A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.056 · Cited by 111
Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors
Jamal, S. M., Eisenberg, M. J., & Christopoulos, S. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.12.037 · Cited by 111
Napoli, P. D., Taccardi, A. A., Grilli, A., Delutiis, M. A., Barsotti, A., Felaco, M., & DeCaterina, R. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.02.008 · Cited by 111
Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease
Hennekens, C. H., Sacks, F. M., Tonkin, A. M., Jukema, J. W., Byington, R. P., Pitt, B., Berry, D. A., Berry, S. M., Ford, N. F., Walker, A. J., et al. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.1.40 · Cited by 111
Do lipid-lowering drugs cause erectile dysfunction? A systematic review
Rizvi, K. (2002) · Family Practice · doi:10.1093/fampra/19.1.95 · Cited by 111
Preventive medication use among persons with limited life expectancy
Maddison, A. R., Fisher, J. E., & Johnston, G. M. (2011) · Progress in Palliative Care · doi:10.1179/174329111x576698 · Cited by 111
Dyslipidemia in Visceral Obesity
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2004) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200404040-00004 · Cited by 111
Safety Profiles for the HMG-CoA Reductase Inhibitors
Davidson, M. H. (2001) · Drugs · doi:10.2165/00003495-200161020-00005 · Cited by 111
Harris, R., Donahue, K. E., Rathore, S. S., Frame, P., Woolf, S. H., & Lohr, K. N. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-3-200302040-00015 · Cited by 111
Ahmed, S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl220 · Cited by 110
Role of disease risk scores in comparative effectiveness research with emerging therapies
Glynn, R. J., Gagne, J. J., & Schneeweiß, S. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3231 · Cited by 110
Sasaki, J. D., Ikeda, Y., Kuribayashi, T., Kajiwara, K., Biro, S., Yamamoto, K., Ageta, M., Kobori, S., Saikawa, T., Otonari, T., et al. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.017 · Cited by 110
Gender Disparities in the Quality of Cardiovascular Disease Care in Private Managed Care Plans
Chou, A. F., Scholle, S. H., Weisman, C. S., Bierman, A. S., Correa‐de‐Araujo, R., & Mosca, L. J. (2007) · Women s Health Issues · doi:10.1016/j.whi.2007.03.002 · Cited by 110
Atorvastatin Prevents End-Organ Injury in Salt-Sensitive Hypertension
Zhou, M.-S., Jaimes, E. A., & Raij, L. R. (2004) · Hypertension · doi:10.1161/01.hyp.0000136395.06810.cf · Cited by 110
Screening for Statin-Related Toxicity
Smith, C. C., Bernstein, L. I., Davis, R. B., Rind, D. M., & Shmerling, R. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.6.688 · Cited by 110
Global cardiovascular disease prevention: time to get serious
Beaglehole, R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05784-1 · Cited by 110
Kawashima, S., Yamashita, T., Miwa, Y., Ozaki, M., Namiki, M., Hirase, T., Inoue, N., Hirata, K., & Yokoyama, M. (2003) · Stroke · doi:10.1161/01.str.0000048213.18751.52 · Cited by 110
Indolfi, C., Lorenzo, E. D., Perrino, C., Stingone, A. M., Curcio, A., Torella, D., Cittadini, A., Cardone, L., Coppola, C., Cavuto, L., et al. (2002) · Circulation · doi:10.1161/01.cir.0000034047.70205.97 · Cited by 110
Semb, A. G., van Wissen, S., Ueland, T., Smilde, T. J., Wæhre, T., Trip, M. D., Frøland, S. S., Kastelein, J. J. P., Gullestad, L. L., Pedersen, T. R., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02718-3 · Cited by 110
Alehagen, U., Benson, L., Edner, M., Dahlström, U., & Lund, L. H. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002143 · Cited by 109
Hossain, S. S., Hossainy, S., Bazilevs, Y., Calo, V. M., & Hughes, T. J. R. (2011) · Computational Mechanics · doi:10.1007/s00466-011-0633-2 · Cited by 109
Zhou, Z., Rahme, E., & Pilote, L. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.003 · Cited by 109
Sata, M., Nishimatsu, H., Suzuki, E., Sugiura, S., Yoshizumi, M., Ouchi, Y., Hirata, Y., & Nagai, R. (2001) · The FASEB Journal · doi:10.1096/fj.01-0415fje · Cited by 109
Asztalos, B. F., Horvath, K. V., McNamara, J. R., Roheim, P. S., Rubinstein, J. J., & Schaefer, E. J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00149-1 · Cited by 109
Wannamethee, S. G., Shaper, A. G., & LENNON, L. T. (2004) · Heart · doi:10.1136/hrt.2003.026104 · Cited by 109
Treatment of Cardiovascular and Renal Risk Factors in the Diabetic Hypertensive
Sowers, J. R., & Haffner, S. M. (2002) · Hypertension · doi:10.1161/01.hyp.0000042097.39655.b7 · Cited by 109
Hamilton‐Craig, I. R. (2001) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2001.tb143683.x · Cited by 109
Velasco, J. A., Cosín, J., López-Sendón, J. L., de Teresa, E., de Oya, M., & Sellers, G. (2002) · Revista Española de Cardiología · doi:10.1016/s0300-8932(02)76708-0 · Cited by 108
Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins
Miettinen, T. A., Gylling, H. K., Lindbohm, N., Miettinen, T. E., Rajaratnam, R., & Relas, H. (2003) · Journal of Laboratory and Clinical Medicine · doi:10.1067/mlc.2003.9 · Cited by 108
Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality
Elkind, M. S. V., Flint, A. C., Sciacca, R. R., & Sacco, R. L. (2005) · Neurology · doi:10.1212/01.wnl.0000171746.63844.6a · Cited by 108
Intensive Integrated Therapy of Type 2 Diabetes
Gæde, P., & Pedersen, O. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s39 · Cited by 108
Pharmacological Treatment and Current Management of Peripheral Artery Disease
Bonaca, M. P., & Creager, M. A. (2015) · Circulation Research · doi:10.1161/circresaha.114.303505 · Cited by 107
Nanayakkara, P. W. B. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.12.1262 · Cited by 107
Cardiovascular Risk and Statin Therapy Considerations in Women
Gheorghe, G., Toth, P. P., BUNGAU, S. G., Behl, T., Ilie, M., Stoian, A. P., Bratu, O. G., Bacalbaşa, N., Rus, M., & Diaconu, C. C. (2020) · Diagnostics · doi:10.3390/diagnostics10070483 · Cited by 106
Hippisley‐Cox, J., Parker, C., Coupland, C. A. C., & Vinogradova, Y. (2007) · Heart · doi:10.1136/hrt.2006.110171 · Cited by 106
Comparative effects of lipid-lowering therapies
Davidson, M. H., & Toth, P. P. (2004) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2004.04.007 · Cited by 106
Hardie, K., Jamrozik, K. D., Hankey, G. J., Broadhurst, R. J., & Anderson, C. S. (2005) · Cerebrovascular Diseases · doi:10.1159/000083253 · Cited by 106
Jafri, H., Alsheikh-Ali, A. A. A., & Karas, R. H. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-12-201012210-00006 · Cited by 105
Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease
Shapiro, M. D., & Fazio, S. (2017) · F1000Research · doi:10.12688/f1000research.9845.1 · Cited by 103
The therapeutic impacts of tocotrienols in type 2 diabetic patients with hyperlipidemia
Baliarsingh, S., Beg, Z. H., & Ahmad, J. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.02.020 · Cited by 105
Trends in Complexity of Diabetes Care in the United States From 1991 to 2000
Grant, R. W. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.10.1134 · Cited by 105
Are statins anti-inflammatory?
Blake, G. J., & Ridker, P. M. (2000) · Trials · doi:10.1186/cvm-1-3-161 · Cited by 105
Control de la colesterolemia en España, 2000. Un instrumento para la prevención cardiovascular
Pérez, I. P., Álvarez, F. V., López, P. M., Jiménez, F. P., Galán, A. M., Casasnovas, J. A., Banegas, J. R. B., Abadal, L. T., Rodríguez‐Artalejo, F., & López, E. G. (2000) · Revista Española de Cardiología · doi:10.1016/s0300-8932(00)75163-3 · Cited by 105
Dyslipidemia in women: etiology and management
Toth, P. P., & Phan, B. A. P. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s38133 · Cited by 104
HDL and cardiovascular disease
Nicholls, S. J., & Nelson, A. J. (2019) · Pathology · doi:10.1016/j.pathol.2018.10.017 · Cited by 104
Clearfield, M. B., Downs, J. R., Weis, S. E., Whitney, E. J., Kruyer, W. B., Shapiro, D. R., Stein, E. A., Langendörfer, A., Beere, P. A., & Gotto, A. M. (2001) · Journal of Women s Health & Gender-Based Medicine · doi:10.1089/152460901317193549 · Cited by 104
From Inuit to Implementation: Omega-3 Fatty Acids Come of Age
O’Keefe, J. H., & Harris, W. S. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.6.607 · Cited by 104
Yang, Z., Kozai, T., van der Loo, B., Viswambharan, H., Lachat, M. L., Turina, M. I., Maliñski, T., & Lüscher, T. F. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00924-4 · Cited by 104
Metadata
- Authors
- The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1998-11-05
- Volume
- 339
- Issue
- 19
- Pages
- 1349-1357
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W38523360
- Cited by
- 5,261
- References
- 21
- Citations by year
- 2026: 19 · 2025: 24 · 2024: 57 · 2023: 53 · 2022: 60 · 2021: 58 · 2020: 72 · 2019: 82 · 2018: 81 · 2017: 94 · 2016: 114 · 2015: 111 · 2014: 118 · 2013: 167 · 2012: 147
- FWCI
- 312.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- pravastatin, coronary artery disease, statin therapy, cholesterol-lowering therapy, cardiovascular mortality, myocardial infarction, unstable angina, stroke, coronary revascularization, total cholesterol, secondary prevention, lipid-lowering diet
- MeSH terms
- Adult, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Humans, Lipids, Male, Middle Aged, Mortality, Myocardial Infarction, Risk, Incidence, Pravastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
